We know you’re concerned about seizures

We also know seizures aren’t your only concern.

Help Your Loved One Take Control

Know the Caregiving Basics

Recognize what’s needed. Just as the right treatment can have a tremendous impact, so can the right kind of support. Developing the basic skills you need as a support giver can make a critical difference in the life of the person you care for. A few basic skills are listed below:

Find the Right Approach

Find out how you can help with treatment. From helping to keep track of how often seizures occur to monitoring dosages and any side effects, you may have an important role to play in keeping treatment on track and making sure it is as effective as possible.

Find out how you can help with practical issues. Solving practical problems—anything from transportation issues to having a plan in place for emergencies—can go a long way toward putting the person you care for in control.

Find out what kinds of help you may need from others. Even if you are the primary support giver, you need not be the only one. Just as healthcare professionals help you and your loved one deal with the medical aspects of epilepsy, you needn’t be alone in dealing with the social, psychological, and practical aspects of the condition. Look into support groups in your area or at the national level, and get other friends and family members involved.

Line up substitute caregivers. Whether you are a parent or a peer, and whether your loved one’s condition is well-controlled or severe, the time will come when you will need someone to fill in. Whether it’s a neighbor to look in on the person you care for, a dependable sitter for your child with epilepsy, or even something more demanding, you should be prepared to take time off when YOU need it, or when something urgent comes up. If your options are limited, look into respite care. The more demanding your caregiving is, the more you yourself will need a regular break: Take one.

Keep Learning

Talk to people who’ve been there. Get in touch with others who support people with epilepsy, and find out what has worked for them. Online communities and local organizations are a good place to start.

Ask a healthcare professional. For more facts and information about epilepsy and its treatment, ask the healthcare professional to recommend publications. Many responsible organizations devoted to epilepsy have Web sites, newsletters, and other useful publications.

Get help. To read up on specific topics and concerns, visit the Epilepsy Foundation Web site at

For links to many other epilepsy resources, visit the Epilepsy Information Page of the National www.epilepsyfoundation.org.

Institutes of Health’s National Institute of Neurological Disorders and Stroke (NIH/NINDS). Please see our Important Organizations and Resources page for more.

About TOPAMAX

TOPAMAX is approved as initial monotherapy in patients 10 years of age and older with partial-onset or primary generalized tonic-clonic seizures.

Effectiveness was demonstrated in a controlled trial in patients with epilepsy who had no more than 2 seizures in the 3 months prior to enrollment. Safety and effectiveness in patients who were converted to monotherapy from a previous regimen of other anticonvulsant drugs have not been established in controlled trials.

TOPAMAX is approved as add-on therapy for patients 2 years of age and older with primary generalized tonic-clonic seizures, partial-onset seizures, or seizures associated with Lennox-Gastaut syndrome.

Important Safety Information

Serious risks associated with TOPAMAX include lowered bicarbonate levels in the blood resulting in an increase in the acidity of the blood (metabolic acidosis). Symptoms could include hyperventilation (rapid, deep breathing), tiredness, loss of appetite, irregular heartbeat or changes in the level of alertness. Call your doctor immediately if you get these symptoms. Your doctor may want to do simple blood tests. Chronic, untreated metabolic acidosis may increase the risk for kidney stones or bone disease.

Other serious risks include decreased sweating, increased body temperature, kidney stones, sleepiness, dizziness, confusion, difficulty concentrating, and increased eye pressure (glaucoma). Call your doctor immediately if you have any decrease in vision or eye pain. These problems can lead to blindness if not treated right away.

More common side effects in adults are nervousness, coordination problems, fatigue, speech problems, slowed thinking, memory difficulty, tingling in arms and legs, and double vision; and in children, fatigue, loss of appetite, nervousness, memory difficulty, aggressive behavior, and weight loss.

As monotherapy, the most common side effects of TOPAMAX (in the 400 mg/day group and at a rate higher than the 50 mg/day group) in adults were tingling in arms and legs, weight decrease, sleepiness, loss of appetite, dizziness, and difficulty with memory; and in children, weight decrease, upper respiratory tract infection, tingling in arms and legs, loss of appetite, diarrhea, and mood problems.

In combination with other antiepileptic drugs (AEDs), the most common side effects of TOPAMAX in adults (200 to 400 mg/day) were sleepiness, dizziness, nervousness, loss of muscle coordination, fatigue, speech disorders and related problems, psychomotor slowing, abnormal vision, difficulty with memory, tingling in arms and legs, and double vision; and in children (5 to 9 mg/kg/day), fatigue, sleepiness, loss of appetite, nervousness, difficulty with concentration/attention, difficulty with memory, aggressive reaction, and weight decrease.

Tell your doctor about other medications you take.

Please see full U.S. Prescribing Information.

© Ortho-McNeil Neurologics, Division of Ortho-McNeil-Janssen Pharmaceuticals, Inc. 1999-2009. All rights reserved.

Your use of the information on this site is subject to the terms of our Legal Statement. Please see our Privacy Policy.

This site is published by Ortho-McNeil Neurologics, Division of Ortho-McNeil-Janssen Pharmaceuticals, Inc., which is solely responsible for its contents.

Capitalized product names are trademarks of Ortho-McNeil Neurologics, Division of Ortho-McNeil-Janssen Pharmaceuticals, Inc.

This information is intended for use by our customers, patients and healthcare professionals in the United States only. Ortho-McNeil Neurologics, Division of Ortho-McNeil-Janssen Pharmaceuticals, Inc. recognizes that the Internet is a global communications medium; however, laws, regulatory requirements and medical practices for pharmaceutical products vary from country to country. The prescribing information included here may not be appropriate for use outside the United States.

This site was last modified on: Jul 26 2007 at 13:45:29 EDT